Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time

Conditional survival (CS) is defined as the probability of surviving further t years, given that a patient has already survived s years after the diagnosis of a chronic disease. It is the simplest form of a dynamic prediction in which other events in the course of the disease or biomarker values measured up to time s can be incorporated. CS has attracted attention in recent years either in an absolute or relative form where the latter is based on a comparison with an age-adjusted normal population being highly relevant from a public health perspective. In its absolute form, CS constitutes the quantity of major interest in a clinical context. Given a clinical cohort of patients with a particular type of cancer, absolute CS can be estimated by conditional Kaplan–Meier estimates in strata defined, for example, by age and disease stage or by a conditional version of the Cox and other regression models for time-to-event data. CS can be displayed as a function of the prediction time s in parametric as well as nonparametric fashion. We illustrate the use of absolute CS in a large clinical cohort of patients with multiple myeloma. For investigating CS, it is necessary to ensure almost complete long-term follow-up of the patients enrolled in the clinical cohort and to consider potential age–stage migration as well as changing treatment modalities over time. CS provides valuable and relevant information on how prognosis develops over time. It also serves as a starting point for identifying factors related to long-term survival. Clin Cancer Res; 21(7); 1530–6. ©2015 AACR.

[1]  Kenneth R Hess,et al.  Getting More Out of Survival Data by Using the Hazard Function , 2014, Clinical Cancer Research.

[2]  M. Beksac,et al.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma , 2014, Haematologica.

[3]  M. Jung,et al.  Vorinostat (V) In Combination With Bortezomib (B), Doxorubicin (D) and Dexamethasone (D) (VBDD) In Patients With Refractory Or Relapsed Multiple Myeloma: An Interim Phase I/II Analysis , 2013 .

[4]  Katherine S Panageas,et al.  Dynamic prognostication using conditional survival estimates , 2013, Cancer.

[5]  B. Pégourié,et al.  Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. L. Bergsagel,et al.  Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. , 2013, Blood.

[7]  L. Bolondi,et al.  Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients , 2012, Clinical Cancer Research.

[8]  H. Putter,et al.  Dynamic Prediction in Clinical Survival Analysis , 2011 .

[9]  R. Wäsch,et al.  Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score , 2011, Blood cancer journal.

[10]  J. Besalduch,et al.  Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. , 2011, Blood.

[11]  Greg Yothers,et al.  Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Aldape,et al.  Polymorphisms in the Interleukin-4 Receptor Gene are Associated with Better Survival in Patients with Glioblastoma , 2008, Clinical Cancer Research.

[13]  E Graf,et al.  Quantifying the Predictive Performance of Prognostic Models for Censored Survival Data with Time‐Dependent Covariates , 2008, Biometrics.

[14]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[15]  H. Brenner,et al.  Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.

[16]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Olsen,et al.  Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[19]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[20]  B. O'Sullivan,et al.  Prognostic Factors in Cancer , 1995, UICC International Union Against Cancer / Union Internationale Contre le Cancer.

[21]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.